{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T23:11:18Z","timestamp":1779232278353,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40263-022-00917-1","type":"journal-article","created":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T09:02:50Z","timestamp":1650704570000},"page":"517-527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain"],"prefix":"10.1007","volume":"36","author":[{"given":"Luis","family":"Guti\u00e9rrez\u2010Rojas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"S\u00e1nchez-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Garc\u00eda Dorado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2496-8337","authenticated-orcid":false,"given":"Paola M.","family":"L\u00f3pez Rengel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,23]]},"reference":[{"key":"917_CR1","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"SL James","year":"2018","unstructured":"James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789\u2013858.","journal-title":"Lancet"},{"key":"917_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/epirev\/mxn001","volume":"30","author":"J McGrath","year":"2008","unstructured":"McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67\u201376.","journal-title":"Epidemiol Rev"},{"key":"917_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s12888-020-02538-8","volume":"20","author":"A Orrico-S\u00e1nchez","year":"2020","unstructured":"Orrico-S\u00e1nchez A, L\u00f3pez-Lacort M, Mun\u00f5z-Quiles C, Sanf\u00e9lix-Gimeno G, Di\u00e9z-Domingo J. Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain. BMC Psychiatry. 2020;20:149.","journal-title":"BMC Psychiatry"},{"key":"917_CR4","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1016\/j.fjpsy.2019.10.370","volume":"1","author":"C Toudic","year":"2019","unstructured":"Toudic C, Berrouiguet S, Lemey C, Walter M. Life expectancy, quality of life and schizophrenia. French J Psychiatry. 2019;1:S127.","journal-title":"French J Psychiatry."},{"key":"917_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2016.04.046","volume":"186","author":"S Galderisi","year":"2017","unstructured":"Galderisi S, F\u00e4rden A, Kaiser S. Dissecting negative symptoms of schizophrenia: history, assessment, pathophysiological mechanisms and treatment. Schizophr Res. 2017;186:1\u20132.","journal-title":"Schizophr Res"},{"key":"917_CR6","doi-asserted-by":"publisher","first-page":"27208","DOI":"10.3402\/jmahp.v3.27208","volume":"3","author":"IM Majer","year":"2015","unstructured":"Majer IM, Gaughran F, Sapin C, Beillat M, Treur M. Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials. J Mark Access Health Policy. 2015;3:27208.","journal-title":"J Mark Access Health Policy."},{"key":"917_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/15622975.2012.739708","volume":"14","author":"A Hasan","year":"2013","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14:2\u201344.","journal-title":"World J Biol Psychiatry."},{"key":"917_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1471-244X-13-50","volume":"13","author":"R Emsley","year":"2013","unstructured":"Emsley R, Chiliza B, Asmal L, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry. 2013;13:50.","journal-title":"BMC Psychiatry"},{"key":"917_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.neulet.2016.04.044","volume":"669","author":"F Spaniel","year":"2018","unstructured":"Spaniel F, Bakstein E, Anyz J, Hlinka J, Sieger T, Hrdlicka J, et al. Relapse in schizophrenia: definitively not a bolt from the blue. Neurosci Lett. 2018;669:68\u201374.","journal-title":"Neurosci Lett"},{"key":"917_CR10","first-page":"1161","volume":"11","author":"J Xiao","year":"2015","unstructured":"Xiao J, Mi W, Li L, Shi Y, Zhang H. High relapse rate and poor medication adherence in the chinese population with schizophrenia: results from an observational survey in the people\u2019s Republic of China. Neuropsychiatr Dis Treat. 2015;11:1161\u20137.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"917_CR11","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jpsychires.2012.05.001","volume":"46","author":"O Caseiro","year":"2012","unstructured":"Caseiro O, P\u00e9rez-Iglesias R, Mata I, Mart\u00ednez-Garcia O, Pelayo-Ter\u00e1n JM, Tabares-Seisdedos R, et al. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. J Psychiatr Res. 2012;46:1099\u2013105.","journal-title":"J Psychiatr Res"},{"key":"917_CR12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1055\/a-1167-6057","volume":"25","author":"H Thiem","year":"2020","unstructured":"Thiem H, Folkerts H, V\u00f6lkel L. Short-acting antipsychotics or long-acting injectables? A treatment comparison in patients with schizophrenia. Gesundheitsokonomie und Qual. 2020;25:170\u20138.","journal-title":"Gesundheitsokonomie und Qual."},{"key":"917_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.rpsm.2018.03.006","volume":"12","author":"C Arango","year":"2019","unstructured":"Arango C, Baeza I, Bernardo M, Ca\u00f1as F, de Dios C, D\u00edaz-Mars\u00e1 M, et al. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain. Ed E, editor. Rev Psiquiatr Salud Ment. 2019;12:92\u2013105.","journal-title":"Rev Psiquiatr Salud Ment."},{"key":"917_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/schbul\/sbs150","volume":"40","author":"T Kishimoto","year":"2014","unstructured":"Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40:192\u2013213.","journal-title":"Schizophr Bull"},{"key":"917_CR15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.4088\/JCP.12r08167","volume":"74","author":"NY Kirson","year":"2013","unstructured":"Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74:568\u201375.","journal-title":"J Clin Psychiatry"},{"key":"917_CR16","doi-asserted-by":"publisher","first-page":"957","DOI":"10.4088\/JCP.13r08440","volume":"74","author":"T Kishimoto","year":"2013","unstructured":"Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013;74:957\u201365.","journal-title":"J Clin Psychiatry"},{"key":"917_CR17","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1176\/appi.ps.201500455","volume":"67","author":"JP MacEwan","year":"2016","unstructured":"MacEwan JP, Kamat SA, Duffy RA, Seabury S, Chou JW, Legacy SN, et al. Hospital readmission rates among patients with schizophrenia treated with long-acting injectables or oral antipsychotics. Psychiatr Serv. 2016;67:1183\u20138.","journal-title":"Psychiatr Serv"},{"key":"917_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40263-021-00815-y","volume":"35","author":"D Lin","year":"2021","unstructured":"Lin D, Thompson-Leduc P, Ghelerter I, Nguyen H, Lafeuille MH, Benson C, et al. Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis. CNS Drugs. 2021;35:469\u201381.","journal-title":"CNS Drugs"},{"key":"917_CR19","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1007\/s12325-018-0785-y","volume":"35","author":"T Yan","year":"2018","unstructured":"Yan T, Greene M, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of aripiprazole once-monthly 400 mg (AOM 400) versus oral antipsychotics in patients with schizophrenia or bipolar I disorder: a real-world study using US claims data. Adv Ther. 2018;35:1612\u201325.","journal-title":"Adv Ther"},{"key":"917_CR20","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1017\/S0033291717003051","volume":"48","author":"R Patel","year":"2018","unstructured":"Patel R, Chesney E, Taylor M, Taylor D, McGuire P. Is paliperidone palmitate more effective than other long-acting injectable antipsychotics? Psychol Med. 2018;48:1616\u201323.","journal-title":"Psychol Med"},{"key":"917_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12888-017-1358-3","volume":"17","author":"D Pilon","year":"2017","unstructured":"Pilon D, Muser E, Lefebvre P, Kamstra R, Emond B, Joshi K. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia. BMC Psychiatry. 2017;17:207.","journal-title":"BMC Psychiatry"},{"key":"917_CR22","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","volume":"72","author":"J Berwaerts","year":"2015","unstructured":"Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia a randomized clinical trial. JAMA Psychiat. 2015;72:830\u20139.","journal-title":"JAMA Psychiat"},{"key":"917_CR23","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1016\/j.clinthera.2018.07.011","volume":"40","author":"M DerSarkissian","year":"2018","unstructured":"DerSarkissian M, Lefebvre P, Joshi K, Brown B, Lafeuille MH, Bhak RH, et al. Health care resource utilization and costs associated with transitioning to 3-month paliperidone palmitate among US veterans. Clin Ther. 2018;40:1496\u2013508.","journal-title":"Clin Ther"},{"key":"917_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1192\/j.eurpsy.2021.2243","volume":"64","author":"I Clark","year":"2021","unstructured":"Clark I, Wallman P, Cornelius V, Taylor D. Factors predicting relapse and treatment discontinuation with paliperidone 3-monthly long-acting injection: a 2-year naturalistic follow-up study. Eur Psychiatry. 2021;64:68.","journal-title":"Eur Psychiatry"},{"key":"917_CR25","doi-asserted-by":"publisher","first-page":"pyw018","DOI":"10.1093\/ijnp\/pyw018","volume":"19","author":"AJ Savitz","year":"2016","unstructured":"Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Janik A, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016;19:pyw018.","journal-title":"Int J Neuropsychopharmacol"},{"key":"917_CR26","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/13696998.2017.1351370","volume":"20","author":"TR Einarson","year":"2017","unstructured":"Einarson TR, Bereza BG, Garcia Llinares I, Gonz\u00e1lez Mart\u00edn Moro B, Tedouri F, Van Impe K. Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain. J Med Econ. 2017;20:1039\u201347.","journal-title":"J Med Econ"},{"key":"917_CR27","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1080\/13696998.2017.1363050","volume":"20","author":"TR Einarson","year":"2017","unstructured":"Einarson TR, Bereza BG, Tedouri F, Van Impe K, Denee TR, Dries PJT. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands. J Med Econ. 2017;20:1187\u201399.","journal-title":"J Med Econ"},{"key":"917_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/0962280211403603","volume":"22","author":"G Danaei","year":"2013","unstructured":"Danaei G, Rodr\u00edguez LAG, Cantero OF, Logan R, Hern\u00e1n MA. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res. 2013;22:70\u201396.","journal-title":"Stat Methods Med Res"},{"key":"917_CR29","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1192\/bjp.184.4.346","volume":"184","author":"S Almond","year":"2004","unstructured":"Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184:346\u201351.","journal-title":"Br J Psychiatry"},{"key":"917_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/YIC.0000000000000155","volume":"32","author":"N Nikoli\u0107","year":"2017","unstructured":"Nikoli\u0107 N, Page N, Akram A, Khan M. The impact of paliperidone palmitate long-acting injection on hospital admissions in a mental health setting. Int Clin Psychopharmacol. 2017;32:95\u2013102.","journal-title":"Int Clin Psychopharmacol"},{"key":"917_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/YIC.0000000000000285","volume":"34","author":"S Pappa","year":"2019","unstructured":"Pappa S, Mason K, Howard E. Long-term effects of paliperidone palmitate on hospital stay and treatment continuation. Int Clin Psychopharmacol. 2019;34:305\u201311.","journal-title":"Int Clin Psychopharmacol"},{"key":"917_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/YIC.0000000000000339","volume":"36","author":"JA Garci\u00e1-Carmona","year":"2020","unstructured":"Garci\u00e1-Carmona JA, Simal-Aguado J, Campos-Navarro MP, Valdivia-Mu\u00f1oz F, Galindo-Tovar A. Evaluation of long-acting injectable antipsychotics with the corresponding oral formulation in a cohort of patients with schizophrenia: a real-world study in Spain. Int Clin Psychopharmacol. 2020;36:18\u201324.","journal-title":"Int Clin Psychopharmacol"},{"key":"917_CR33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","volume":"8","author":"T Kishimoto","year":"2021","unstructured":"Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre\u2013post studies. Lancet Psychiatry. 2021;8:387\u2013404.","journal-title":"Lancet Psychiatry"},{"key":"917_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fpsyt.2020.00048","volume":"11","author":"K Slankamenac","year":"2020","unstructured":"Slankamenac K, Heidelberger R, Keller DI. Prediction of recurrent emergency department visits in patients with mental disorders. Front Psychiatry. 2020;11:48.","journal-title":"Front Psychiatry."},{"key":"917_CR35","first-page":"192","volume":"12","author":"M Foley","year":"2011","unstructured":"Foley M, Kifaieh N, Mallon WK. Financial impact of emergency department crowding. West J Emerg Med. 2011;12:192\u20137.","journal-title":"West J Emerg Med"},{"key":"917_CR36","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1067\/mem.2002.128012","volume":"40","author":"LD Richardson","year":"2002","unstructured":"Richardson LD, Asplin BR, Lowe RA. Emergency department crowding as a health policy issue: past development, future directions. Ann Emerg Med. 2002;40:388\u201393.","journal-title":"Ann Emerg Med"},{"key":"917_CR37","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","volume":"169","author":"A Schreiner","year":"2015","unstructured":"Schreiner A, Aadamsoo K, Altamura AC, Franco M, Gorwood P, Neznanov NG, et al. Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. Schizophr Res. 2015;169:393\u20139.","journal-title":"Schizophr Res"},{"key":"917_CR38","doi-asserted-by":"publisher","first-page":"204512532092634","DOI":"10.1177\/2045125320926347","volume":"10","author":"MP Garcia-Portilla","year":"2020","unstructured":"Garcia-Portilla MP, Llorca P-M, Maina G, Bozikas VP, Devrimci-Ozguven H, Kim S-W, et al. Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia. Ther Adv Psychopharmacol. 2020;10:204512532092634.","journal-title":"Ther Adv Psychopharmacol."},{"key":"917_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jpsychires.2022.01.044","volume":"148","author":"P Wallman","year":"2022","unstructured":"Wallman P, Clark I, Taylor D. Effect of 3-monthly paliperidone palmitate on hospitalisation in a naturalistic schizophrenia cohort\u2014a five-year mirror image study. J Psychiatr Res. 2022;148:131\u20136.","journal-title":"J Psychiatr Res"},{"key":"917_CR40","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.2147\/NDT.S221242","volume":"16","author":"M Mathews","year":"2020","unstructured":"Mathews M, Gopal S, Singh A, Nuamah I, Pungor K, Tan W, et al. Comparison of relapse prevention with 3 different paliperidone formulations in patients with schizophrenia continuing versus discontinuing active antipsychotic treatment: a post-hoc analysis of 3 similarly designed randomized studies. Neuropsychiatr Dis Treat. 2020;16:1533\u201342.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"917_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1192\/j.eurpsy.2021.4","volume":"64","author":"E Laing","year":"2021","unstructured":"Laing E, Taylor D. Relapse and frequency of injection of monthly paliperidone palmitate\u2014a retrospective case\u2013control study. Eur Psychiatry. 2021;64:11.","journal-title":"Eur Psychiatry"},{"key":"917_CR42","doi-asserted-by":"publisher","first-page":"204512532098150","DOI":"10.1177\/2045125320981500","volume":"10","author":"K Pungor","year":"2020","unstructured":"Pungor K, Bozikas VP, Emsley R, Llorca P-M, Gopal S, Mathews M, et al. Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes. Ther Adv Psychopharmacol. 2020;10:204512532098150.","journal-title":"Ther Adv Psychopharmacol."},{"key":"917_CR43","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.schres.2016.09.034","volume":"179","author":"SD Targum","year":"2017","unstructured":"Targum SD, Risinger R, Du Y, Pendergrass JC, Jamal HH, Silverman BL. Effect of patient age on treatment response in a study of the acute exacerbation of psychosis in schizophrenia. Schizophr Res. 2017;179:64\u20139.","journal-title":"Schizophr Res"},{"key":"917_CR44","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.3109\/08039488.2014.990919","volume":"69","author":"AC Altamura","year":"2015","unstructured":"Altamura AC, Serati M, Buoli M. Is duration of illness really influencing outcome in major psychoses? Nord J Psychiatry. 2015;69:1685\u201399.","journal-title":"Nord J Psychiatry"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00917-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00917-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00917-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T05:23:10Z","timestamp":1652246590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00917-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,23]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["917"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00917-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,23]]},"assertion":[{"value":"14 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Janssen. Medical writing and editorial support were funded by Janssen.\u00a0Open access publication was funded by Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"LGR has been a speaker and advisory board member for Janssen-Cilag, Angelini, Casen-Recordati, Lundbeck, Otsuka, Novartis, GSK, and Pfizer. SSA has been a speaker and advisory board member for Janssen-Cilag, Angelini, Casen-Recordati, Lundbeck, Otsuka, Qualigen, and Adamed. MGD and PLR are full-time employees of Janssen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted according to guidelines on observational post-authorization studies for medicinal products for human use specified in Orden SAS\/3470\/2009 of the Spanish Agency of Medicines and Medical Devices (AEMPS). The study was also conducted according to good clinical practice guidelines (International Conference for Harmonization) and the Declaration of Helsinki and was approved by a public hospital ethics committee in Spain.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All identifiable personal information was removed for privacy protection prior to data acquisition, so the requirement for informed consent was waived.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data analyzed in this study are not publicly available according to the licensing agreement with IQVIA.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MGD and PLR designed the study concept. LGR, SSA, MGD, and PLR participated in data analysis and interpretation and in the review and editing of the article. LGR and SSA wrote the first draft. All authors critically reviewed the manuscript. All authors provided input into the drafting of the manuscript, have read, and approved the final submitted version to be published, and agree to be accountable for the work as a whole.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}